

Introduction and Objectives

SCIENCE

PHILIP MORRIS INTERNATIONAL

Worm-on-a-chip technology: An emerging 3R model in toxicity testing

Carole Mathis^{1*}, Laurent Mouchiroud², Matteo Cornaglia², Daniel Smart¹, Mohamed Amin Choukrallah¹, Karsta Luettich¹, Julia Hoeng¹, and Manuel C. Peitsch¹

Competing Financial Interest – The research described in this poster was sponsored by Philip Morris International.

1PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland 2Nagi Bioscience SA, Bâtiment C, EPFL Innovation Park, CH-1015 Lausanne, Switzerland

Conclusions

Results

2791/P404

Figure 1. Study design and exposure timeline. (A) N2 wild-type (WT) strain worms are grown on solid nematode growth medium agar plates and harvested in complete S-medium at the adult stage (P0). Eggs from the P0 population are hatched, and this L1 population is recovered via filtration for synchronization before being injected into a microfluidic chip. L1 worms are then fed with bacterial medium and continuously exposed to compounds of interest either during development from L1 to adult stage (B) or from L4 to adult stage (C). Live monitoring of each worm is performed every hour throughout the whole *experiment at constant temperature.* Worm growth (control

Figure 2. Overview of data analysis pipeline. Time-lapse brightfield images of each worm in a chip channel are processed by using Nagi Bioscience's software algorithms, and quantitative data for various endpoints are collected and computed. As an example, worm area data are plotted against time (top graph), and key parameters of the curve such as the maximum area K and the half-size timing r are then extracted. The bottom graph indicates the number of worms present in each microchamber over the same period, allowing estimation of the number of progeny produced and when the worms were sexually mature.

Figure 7. Thalidomide (top row) and bisphenol A (bottom row): Dose–effect relationship in terms of (A) maximum area (K) and (B) time to reach half the max. size (r). (A,B) The dashed grey and red lines indicate the mean value of the negative control (1% DMSO) and the max. significant variation relative to the negative control, respectively. Each dot corresponds to the mean fold change relative to the negative control for each concentration tested. (C) Dynamic modeling of the toxicity profiles of thalidomide and bisphenol A, with assessment of both K and r parameters.* P<0.05, *** P< 0.01, *** P<0.001, and **** P<0.0001 by unpaired t-test.*

Abbreviations: NOAEL, No-observed-adverse-effect level; LOAEL, Lowest-observed-adverse-effect level.

Table 1. List of chemicals tested (blinded). All compounds were prepared in DMSO (except sodium chloride, which was dissolved in water) before being mixed with the bacterial medium.

Results

Figure 3. Variation in timing to reach the adult stage among single individuals (dots) relative to the whole population.

1- Moullan et al. (2015). Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research. *Cell Rep. 10(10): 1681-1691* 2- Kumar et al. (2010). Anticancer drug 5-fluorouracil induces reproductive and developmental defects in C. elegans. Reprod. Toxicol. *29(4): 415-20* 3- Schenk et al. (2010). The ReProTect Feasibility Study, a novel comprehensive in vitro approach to detect reproductive toxicants. *Reprod. Toxicol. 30: 200-218.*

Figure 4. Variation in the different phenotypes analyzed in the WT population. Each red curve corresponds to the fit modeling of the growth (K) of a single worm. Blue and gray dashed lines correspond to the time to reach half the max. size (r) and the timing when the progeny appears, respectively.

Figure 5. Reproducibility assessment of the filtering protocol for obtaining a synchronous L1 population across 34 replicates. L1 worms synchronized by filtering were injected into a Nagi Bioscience chip for a 5 days of culture. Each channel (x-axis) corresponds to 3–8 microfluidic chambers containing 1–4 worms. Each green dot corresponds to the average time when the first eggs are observed in the corresponding channel. Error bars = SD.

Table 3. Summary of the reproductive toxicology results (see Figure 1C)

Figure 8. Representative images of worms exposed for 20, 40, and 80 h to doxycycline (positive control used in the developmental toxicology assay(1)) and 5-fluorouracil (positive control used in the reproductive toxicology assay(2)) compared with images of worms exposed to 1% DMSO (negative control). The left panel shows a single worm (yellow outline) growing and reaching its adult stage, with appearance of eggs (red) and its L1 progeny (blue) after 80 h in culture. In the middle panel, the effect of doxycycline exposure is characterized by retarded growth and the absence of progeny. In the right panel, exposure to 5-fluorouracil does not impact worm growth or sexual maturity, as shown by the capacity of the animal to lay eggs. The impact of 5 fluorouracil is, in fact, observed at the level of the progeny, where no L1 worms are observed after 80 h of exposure.

Thanks to its tiny size (1-mm long), the nematode *Caenorhabditis elegans* can easily fit into a microfluidic chip, offering a new alternative for animal testing and at the *in vitro* scale. *C. elegans* worms have been widely used for studying development, stress, and aging and have been recently used in environmental toxicology studies. The other advantage of this well-characterized nematode (with >40 years of genetic studies), besides its low maintenance cost and short life cycle, is the fact that many genes and signaling pathways are well-conserved between *C.elegans* and humans.

Nagi Bioscience developed a new worm-on-a-chip technology that combines high-resolution imaging and image analysis algorithms, allowing longitudinal observation at the individual level to evaluate phenotypic readouts such as worm growth, survival, and fertility.

In this collaborative study, a dose–response assay was performed with ten benchmark chemicals (such as lithium chloride, thalidomide, and bisphenol A) to evaluate their potential adverse effects by using this new "*in vitro-like*" model in two exposure scenarios. The phenotypic outcomes of each chemical exposure were compared to those of positive (30 µg/mL doxycycline and 5.15 µg/mL 5-fluorouracil) and negative controls (1% DMSO) to rank the test compounds on the basis of the severity of their adverse effects. Inter-individual variability was also assessed within this assay, by performing synchronization of the worms before injection into the chip. For each test chemical, the no-observed-adverse-effect-level (NOAEL) for each phenotypic endpoint was determined. Examples of the phenotypes observed are presented here, and potential follow-up experiments are discussed.

• Our results show that synchronizing worms at the same developmental stage before chip injection improves interindividual variability for the following phenotypic endpoints: Ø Growth endpoint: Time to reach adult stage (**Figure 3**), maximum size of the worm (K parameter) (**Figures 4**

Ø Precise (automated) and dynamic dosing of compounds (up to 16 doses per chemical per chip), with low

 \triangleright Phenotypic readouts in real time (one picture every hour per condition over 5 days) and at single-animal

- and **6**), and half-time to reach maximum size (r parameter) (**Figures 4** and **6**).
- Ø Fertility endpoint: Time to reach sexual maturity (time when the 1st egg is laid) (**Figure 5**).
- This study highlights the multiple advantages of this new high-throughput screening approach, including: \triangleright Good reproducibility and accurate results by using standardized protocols
	-
	- liquid consumption $(500 \mu L)$ over the full course of the experiment)
	- resolution (Example shown in **Figure 8**)
- seven out of ten chemicals were predicted correctly in *C. elegans*.
- reprotoxicants.

• For each tested chemical, the NOAEL was determined in both experimental set-ups (**Table 2** and **Table 3**), and

• To further evaluate the predictivity of the worm-on-a-chip developmental & reproductive toxicological assays, a larger panel of compounds will have to be tested. Further insights on the modes of action of some of these chemicals (via a systems toxicology approach) could be helpful in determining key pathways sensitive to

References

Thalidomide

극

 Ω .

 $2.0₇$

__ 1.5

1.0∔ غ

 $0.5 -$

alidomide

Bisphenol

 \blacktriangleleft

ANOVA One-way summary $20\frac{1}{2}P = 0.06$ R square = 0.2117

control population. Each dot corresponds to the measurement

